187 related articles for article (PubMed ID: 16227972)
1. Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival.
Allen E; Ding J; Wang W; Pramanik S; Chou J; Yau V; Yang Y
Nature; 2005 Nov; 438(7065):224-8. PubMed ID: 16227972
[TBL] [Abstract][Full Text] [Related]
2. Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin.
Ding J; Liu JJ; Kowal AS; Nardine T; Bhattacharya P; Lee A; Yang Y
J Cell Biol; 2002 Aug; 158(3):427-33. PubMed ID: 12147674
[TBL] [Abstract][Full Text] [Related]
3. Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport.
Ding J; Allen E; Wang W; Valle A; Wu C; Nardine T; Cui B; Yi J; Taylor A; Jeon NL; Chu S; So Y; Vogel H; Tolwani R; Mobley W; Yang Y
Hum Mol Genet; 2006 May; 15(9):1451-63. PubMed ID: 16565160
[TBL] [Abstract][Full Text] [Related]
4. Gigaxonin interacts with tubulin folding cofactor B and controls its degradation through the ubiquitin-proteasome pathway.
Wang W; Ding J; Allen E; Zhu P; Zhang L; Vogel H; Yang Y
Curr Biol; 2005 Nov; 15(22):2050-5. PubMed ID: 16303566
[TBL] [Abstract][Full Text] [Related]
5. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy.
Bomont P; Cavalier L; Blondeau F; Ben Hamida C; Belal S; Tazir M; Demir E; Topaloglu H; Korinthenberg R; Tüysüz B; Landrieu P; Hentati F; Koenig M
Nat Genet; 2000 Nov; 26(3):370-4. PubMed ID: 11062483
[TBL] [Abstract][Full Text] [Related]
6. Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway.
Cleveland DW; Yamanaka K; Bomont P
Hum Mol Genet; 2009 Apr; 18(8):1384-94. PubMed ID: 19168853
[TBL] [Abstract][Full Text] [Related]
7. Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1.
Dequen F; Bomont P; Gowing G; Cleveland DW; Julien JP
J Neurochem; 2008 Oct; 107(1):253-64. PubMed ID: 18680552
[TBL] [Abstract][Full Text] [Related]
8. Genotype-phenotype analysis in patients with giant axonal neuropathy (GAN).
Koop O; Schirmacher A; Nelis E; Timmerman V; De Jonghe P; Ringelstein B; Rasic VM; Evrard P; Gärtner J; Claeys KG; Appenzeller S; Rautenstrauss B; Hühne K; Ramos-Arroyo MA; Wörle H; Moilanen JS; Hammans S; Kuhlenbäumer G
Neuromuscul Disord; 2007 Aug; 17(8):624-30. PubMed ID: 17587580
[TBL] [Abstract][Full Text] [Related]
9. The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test.
Boizot A; Talmat-Amar Y; Morrogh D; Kuntz NL; Halbert C; Chabrol B; Houlden H; Stojkovic T; Schulman BA; Rautenstrauss B; Bomont P
Acta Neuropathol Commun; 2014 Apr; 2():47. PubMed ID: 24758703
[TBL] [Abstract][Full Text] [Related]
10. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.
Johnson-Kerner BL; Ahmad FS; Diaz AG; Greene JP; Gray SJ; Samulski RJ; Chung WK; Van Coster R; Maertens P; Noggle SA; Henderson CE; Wichterle H
Hum Mol Genet; 2015 Mar; 24(5):1420-31. PubMed ID: 25398950
[TBL] [Abstract][Full Text] [Related]
11. Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.
Bomont P; Koenig M
Hum Mol Genet; 2003 Apr; 12(8):813-22. PubMed ID: 12668605
[TBL] [Abstract][Full Text] [Related]
12. Kelch Domain of Gigaxonin Interacts with Intermediate Filament Proteins Affected in Giant Axonal Neuropathy.
Johnson-Kerner BL; Garcia Diaz A; Ekins S; Wichterle H
PLoS One; 2015; 10(10):e0140157. PubMed ID: 26460568
[TBL] [Abstract][Full Text] [Related]
13. A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.
Kang JJ; Liu IY; Wang MB; Srivatsan ES
Hum Genet; 2016 Jul; 135(7):675-84. PubMed ID: 27023907
[TBL] [Abstract][Full Text] [Related]
14. Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
Mahammad S; Murthy SN; Didonna A; Grin B; Israeli E; Perrot R; Bomont P; Julien JP; Kuczmarski E; Opal P; Goldman RD
J Clin Invest; 2013 May; 123(5):1964-75. PubMed ID: 23585478
[TBL] [Abstract][Full Text] [Related]
15. Giant axonal neuropathy.
Hentati F; Hentati E; Amouri R
Handb Clin Neurol; 2013; 115():933-8. PubMed ID: 23931822
[TBL] [Abstract][Full Text] [Related]
16. A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization.
Nath B; Julien JP
J Neurosci; 2023 May; 43(22):4174-4189. PubMed ID: 37137704
[TBL] [Abstract][Full Text] [Related]
17. The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP.
Lin NH; Huang YS; Opal P; Goldman RD; Messing A; Perng MD
Mol Biol Cell; 2016 Dec; 27(25):3980-3990. PubMed ID: 27798231
[TBL] [Abstract][Full Text] [Related]
18. Rab35 Functions in Axon Elongation Are Regulated by P53-Related Protein Kinase in a Mechanism That Involves Rab35 Protein Degradation and the Microtubule-Associated Protein 1B.
Villarroel-Campos D; Henríquez DR; Bodaleo FJ; Oguchi ME; Bronfman FC; Fukuda M; Gonzalez-Billault C
J Neurosci; 2016 Jul; 36(27):7298-313. PubMed ID: 27383602
[TBL] [Abstract][Full Text] [Related]
19. Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment.
Chen PH; Hu J; Wu J; Huynh DT; Smith TJ; Pan S; Bisnett BJ; Smith AB; Lu A; Condon BM; Chi JT; Boyce M
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31944090
[TBL] [Abstract][Full Text] [Related]
20. Axonal Transport Defect in Gigaxonin Deficiency Rescued by Tubastatin A.
Nath B; Phaneuf D; Julien JP
Neurotherapeutics; 2023 Jul; 20(4):1215-1228. PubMed ID: 37268847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
